Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 18, Pages 6838
Publisher
MDPI AG
Online
2020-09-18
DOI
10.3390/ijms21186838
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
- (2020) Stefano Kim et al. BMC CANCER
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer
- (2019) Caroline Laheurte et al. BRITISH JOURNAL OF CANCER
- CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin
- (2019) Jeanne Galaine et al. INTERNATIONAL JOURNAL OF CANCER
- 534PUpdated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
- (2019) S Kim et al. ANNALS OF ONCOLOGY
- Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis
- (2018) Chunqing Lin et al. LANCET INFECTIOUS DISEASES
- Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
- (2018) Stefano Kim et al. LANCET ONCOLOGY
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
- (2017) Van K Morris et al. LANCET ONCOLOGY
- Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
- (2017) Sanja Stevanović et al. SCIENCE
- Direct HPV E6/Myc interactions induce histone modifications, Pol II phosphorylation, and hTERT promoter activation
- (2017) Yiyu Zhang et al. Oncotarget
- Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
- (2016) Susanna Mandruzzato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- CD8 + T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer
- (2016) Liam Masterson et al. EUROPEAN JOURNAL OF CANCER
- International trends in anal cancer incidence rates
- (2016) Farhad Islami et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4+Th1 responses against telomerase in cancer patients
- (2016) Caroline Laheurte et al. OncoImmunology
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Combinatorial Strategies for the Induction of Immunogenic Cell Death
- (2015) Lucillia Bezu et al. Frontiers in Immunology
- Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer
- (2014) F. Parikh et al. CANCER RESEARCH
- Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
- (2014) H. Zelba et al. CLINICAL CANCER RESEARCH
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
- (2013) James W. Hodge et al. INTERNATIONAL JOURNAL OF CANCER
- Up-regulation of Foxp3 participates in progression of cervical cancer
- (2012) Chao Zeng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
- (2012) Y. Godet et al. CLINICAL CANCER RESEARCH
- Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis
- (2012) Benjamin Weide et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
- (2012) Mélanie Bruchard et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now